MIRAPEX
LOE ApproachingNDAORALTABLET
Approved
Jul 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
MIRAPEX by Boehringer Ingelheim is clinical pharmacology mechanism of action pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the d 2 subfamily of dopamine receptors, binding with higher affinity to d 3 than to d 2 or d 4 receptor subtypes. Approved for the signs, symptoms of idiopathic parkinson's disease, moderate-to-severe primary restless legs syndrome (rls). First approved in 1997.
Drug data last refreshed 6d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D 2 subfamily of dopamine receptors, binding with higher affinity to D 3 than to D 2 or D 4 receptor subtypes. Parkinson’s Disease: The…
Worked on MIRAPEX at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.